JP2021500332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500332A5 JP2021500332A5 JP2020521577A JP2020521577A JP2021500332A5 JP 2021500332 A5 JP2021500332 A5 JP 2021500332A5 JP 2020521577 A JP2020521577 A JP 2020521577A JP 2020521577 A JP2020521577 A JP 2020521577A JP 2021500332 A5 JP2021500332 A5 JP 2021500332A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- alkoxy
- halogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 101
- 239000001257 hydrogen Substances 0.000 claims 96
- 229910052736 halogen Inorganic materials 0.000 claims 74
- 150000002367 halogens Chemical class 0.000 claims 74
- 125000005843 halogen group Chemical group 0.000 claims 65
- 150000002431 hydrogen Chemical class 0.000 claims 58
- 125000005842 heteroatom Chemical group 0.000 claims 51
- 125000004093 cyano group Chemical group *C#N 0.000 claims 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 38
- 229910052760 oxygen Inorganic materials 0.000 claims 35
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 19
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 14
- -1 C 1- C 6 alkyl Chemical class 0.000 claims 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 9
- 239000011593 sulfur Substances 0.000 claims 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 150000003951 lactams Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000034656 Contusions Diseases 0.000 claims 3
- 102000003623 TRPC6 Human genes 0.000 claims 3
- 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 claims 3
- 208000034526 bruise Diseases 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- CZSRBTBSPLWAAW-UHFFFAOYSA-N 1-[7-fluoro-6-methoxy-1-[[2-(trifluoromethyl)phenyl]methyl]benzimidazol-2-yl]piperidin-3-amine Chemical compound C=1C=CC=C(C(F)(F)F)C=1CN1C2=C(F)C(OC)=CC=C2N=C1N1CCCC(N)C1 CZSRBTBSPLWAAW-UHFFFAOYSA-N 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 2
- 231100000855 membranous nephropathy Toxicity 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 201000008171 proliferative glomerulonephritis Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574465P | 2017-10-19 | 2017-10-19 | |
| US62/574,465 | 2017-10-19 | ||
| US201862671090P | 2018-05-14 | 2018-05-14 | |
| US62/671,090 | 2018-05-14 | ||
| PCT/US2018/056484 WO2019079578A1 (en) | 2017-10-19 | 2018-10-18 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500332A JP2021500332A (ja) | 2021-01-07 |
| JP2021500332A5 true JP2021500332A5 (enExample) | 2021-10-28 |
| JP7450534B2 JP7450534B2 (ja) | 2024-03-15 |
Family
ID=66173507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521577A Active JP7450534B2 (ja) | 2017-10-19 | 2018-10-18 | ベンズイミダゾール誘導体及びその用途 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11332459B2 (enExample) |
| EP (1) | EP3697410B1 (enExample) |
| JP (1) | JP7450534B2 (enExample) |
| KR (1) | KR102697255B1 (enExample) |
| CN (1) | CN111417394B (enExample) |
| AU (1) | AU2018351059B2 (enExample) |
| BR (1) | BR112020007589A8 (enExample) |
| CA (1) | CA3079081A1 (enExample) |
| CL (1) | CL2020001020A1 (enExample) |
| CO (1) | CO2020004669A2 (enExample) |
| ES (1) | ES3004333T3 (enExample) |
| HR (1) | HRP20250272T1 (enExample) |
| HU (1) | HUE070649T2 (enExample) |
| IL (1) | IL273839B (enExample) |
| MA (1) | MA50413A (enExample) |
| MX (1) | MX2020003993A (enExample) |
| PH (1) | PH12020550265A1 (enExample) |
| PL (1) | PL3697410T3 (enExample) |
| SA (1) | SA520411787B1 (enExample) |
| SG (1) | SG11202003502VA (enExample) |
| TW (1) | TWI816704B (enExample) |
| UY (1) | UY37941A (enExample) |
| WO (1) | WO2019079578A1 (enExample) |
| ZA (1) | ZA202002762B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10703733B2 (en) | 2018-05-14 | 2020-07-07 | Gilead Sciences, Inc. | MCL-1 inhibitors |
| JP7227398B2 (ja) * | 2019-04-11 | 2023-02-21 | 帝人ファーマ株式会社 | ベンズイミダゾール誘導体及びその使用 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| US11325891B2 (en) | 2019-11-26 | 2022-05-10 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| AR121846A1 (es) | 2020-04-16 | 2022-07-13 | Teijin Pharma Ltd | Derivado de arilo o heteroarilo |
| MX2022012923A (es) * | 2020-04-16 | 2022-11-16 | Boehringer Ingelheim Int | Inhibidores de trpc6 para tratar afecciones respiratorias. |
| US12202782B2 (en) | 2020-11-19 | 2025-01-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| US20240307375A1 (en) * | 2021-06-29 | 2024-09-19 | Osaka University | Pharmaceutical composition for preventing and/or treating kidney injury, and autophagy activator |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2618435B1 (fr) | 1987-07-23 | 1989-10-27 | Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| US5670501A (en) | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| DE60140708D1 (de) | 2000-08-10 | 2010-01-14 | Mitsubishi Tanabe Pharma Corp | Prolinderivative und deren Verwendung als Medikamente |
| NZ531679A (en) | 2001-10-15 | 2005-02-25 | Janssen Pharmaceutica Nv | Novel substituted 4-phenyl-4-[1H-imidazol-2-YL]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
| DE60216310T2 (de) | 2001-10-15 | 2007-06-21 | Janssen Pharmaceutica N.V. | Substituierte 4-phenyl-4-(1h-imidazol-2-yl)-piperidinderivate zur verringerung von ischämischer schädigung |
| DE60329513D1 (de) | 2002-07-30 | 2009-11-12 | Banyu Pharma Co Ltd | Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff |
| US7582761B2 (en) * | 2002-10-17 | 2009-09-01 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| JPWO2005051949A1 (ja) * | 2003-11-26 | 2007-06-21 | 住友製薬株式会社 | 新規縮合イミダゾール誘導体 |
| DE102004017932A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| WO2006010283A1 (en) | 2004-07-28 | 2006-02-02 | Universität Zürich | Prevention and treatment of thrombus formation |
| US20100267717A1 (en) | 2005-07-29 | 2010-10-21 | 4Sc Ag | Novel Heterocyclic NF-kB Inhibitors |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| DE102005012875B4 (de) | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
| DE102005012874A1 (de) * | 2005-03-19 | 2006-09-21 | Sanofi-Aventis Deutschland Gmbh | Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7632454B2 (en) * | 2005-04-06 | 2009-12-15 | North Carolina State University | Dense, shaped articles constructed of a refractory material and methods of preparing such articles |
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| AU2006301892A1 (en) | 2005-10-07 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Combined use of DPP IV inhibitors and gastrin compounds |
| JP2009541454A (ja) | 2006-07-03 | 2009-11-26 | ノイロサーチ アクティーゼルスカブ | モノアミン再摂取阻害剤及びカリウムチャネル活性剤の併用 |
| MX2009001913A (es) | 2006-08-23 | 2009-03-06 | Pfizer Prod Inc | Compuestos de pirimidona como inhibidores de gsk-3. |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| WO2008100977A2 (en) | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
| WO2008153701A1 (en) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| CA2695008A1 (en) | 2007-07-30 | 2009-02-05 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| US20090176792A1 (en) | 2008-01-07 | 2009-07-09 | Auspex Pharmaceuticals, Inc. | Substituted dibenzhydrylpiperazines |
| KR20100101055A (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물 |
| EP2440231B1 (en) | 2009-06-10 | 2019-12-04 | NoNO Inc. | Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| EP2368876A1 (en) | 2010-03-01 | 2011-09-28 | Sanofi | Derivatives of aminoindanes, their preparation and their application in therapeutics |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
| EP3009427B1 (en) | 2011-03-03 | 2019-12-18 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP2698367A1 (en) * | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
| GB201223265D0 (en) | 2012-12-21 | 2013-02-06 | Selvita Sa | Novel benzimidazole derivatives as kinase inhibitors |
| JP2016513112A (ja) | 2013-02-18 | 2016-05-12 | ザ スクリプス リサーチ インスティテュート | 治療的潜在能力を有するバソプレッシン受容体のモジュレーター |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| CN106879256B (zh) | 2014-07-31 | 2021-08-03 | 韩国巴斯德研究所 | 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用 |
| WO2016168660A1 (en) | 2015-04-17 | 2016-10-20 | Forma Therapeutics, Inc. | 3-spiro-7-hydroxamic acid tetralins as hdac inhibitors |
| WO2017052394A1 (en) | 2015-09-23 | 2017-03-30 | Uniwersytet Jagielloński | Imidazopyridine compounds and their use as 5-ht6 receptor ligands |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| GB201603311D0 (en) | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
| US10501421B1 (en) * | 2017-01-27 | 2019-12-10 | Vanderbilt University | Substituted benzimidazoles as modulators of Ras signaling |
-
2018
- 2018-10-18 CA CA3079081A patent/CA3079081A1/en active Pending
- 2018-10-18 EP EP18867844.5A patent/EP3697410B1/en active Active
- 2018-10-18 IL IL273839A patent/IL273839B/en unknown
- 2018-10-18 KR KR1020207013744A patent/KR102697255B1/ko active Active
- 2018-10-18 ES ES18867844T patent/ES3004333T3/es active Active
- 2018-10-18 HR HRP20250272TT patent/HRP20250272T1/hr unknown
- 2018-10-18 HU HUE18867844A patent/HUE070649T2/hu unknown
- 2018-10-18 BR BR112020007589A patent/BR112020007589A8/pt active IP Right Grant
- 2018-10-18 PL PL18867844.5T patent/PL3697410T3/pl unknown
- 2018-10-18 WO PCT/US2018/056484 patent/WO2019079578A1/en not_active Ceased
- 2018-10-18 US US16/754,349 patent/US11332459B2/en active Active
- 2018-10-18 AU AU2018351059A patent/AU2018351059B2/en active Active
- 2018-10-18 SG SG11202003502VA patent/SG11202003502VA/en unknown
- 2018-10-18 MX MX2020003993A patent/MX2020003993A/es unknown
- 2018-10-18 CN CN201880077655.5A patent/CN111417394B/zh active Active
- 2018-10-18 MA MA050413A patent/MA50413A/fr unknown
- 2018-10-18 JP JP2020521577A patent/JP7450534B2/ja active Active
- 2018-10-19 TW TW107137075A patent/TWI816704B/zh active
- 2018-10-19 UY UY0001037941A patent/UY37941A/es not_active Application Discontinuation
-
2020
- 2020-04-14 PH PH12020550265A patent/PH12020550265A1/en unknown
- 2020-04-16 CO CONC2020/0004669A patent/CO2020004669A2/es unknown
- 2020-04-16 CL CL2020001020A patent/CL2020001020A1/es unknown
- 2020-04-17 SA SA520411787A patent/SA520411787B1/ar unknown
- 2020-05-14 ZA ZA2020/02762A patent/ZA202002762B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500332A5 (enExample) | ||
| US10301280B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| EP2892534B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP5898067B2 (ja) | がん及び非新生物性状態の治療方法 | |
| TWI535442B (zh) | A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine | |
| JP2017505762A5 (enExample) | ||
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| US20150284397A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2021502387A5 (enExample) | ||
| JP2020533347A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2019533696A (ja) | Ｂ型肝炎ウイルス感染症の処置及び予防のための新規なテトラヒドロピリドピリミジン | |
| JP7732668B2 (ja) | 窒素含有多環式縮合環系化合物、その薬学的組成物、製造方法及び用途 | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| KR20210049862A (ko) | 일종의 신형 퀴놀린 유도체 억제제 | |
| JP2016525104A5 (enExample) | ||
| AU2021403015A1 (en) | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof | |
| JP2015507004A5 (enExample) | ||
| US20160159814A1 (en) | Glycine transporter inhibitor | |
| US20160031874A1 (en) | Substituted aminothiazoles for the treatment of tuberculosis | |
| CN105308024B (zh) | 二环式含氮芳香族杂环酰胺化合物 | |
| JP2009537606A5 (enExample) | ||
| JP2020531485A5 (enExample) | ||
| KR20200104336A (ko) | 수용체 티로신 키나제 억제제의 Tyro3, Axl 및 Mertk (TAM) 패밀리로서의 헤테로고리 화합물 | |
| KR102939670B1 (ko) | Pdl1 체크포인트 억제제로서의 헤테로고리 면역조절제 |